Global Capecitabine Market – Industry Analysis and Forecast (2019-2026): By Drug Formulation, Application and Region.

Global Capecitabine Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2026, at a CAGR of around XX % during a forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region To know about the Research Methodology:-Request Free Sample Report Capecitabine is a chemotherapeutic agent used in the treatment of colorectal cancers & metastatic breast. Cancer is the second leading cause of death worldwide–around XX Mn deaths every year are caused by cancer, according to WHO. Additionally, more than 70% of deaths occur in low and middle-income countries. The global demand for chemotherapeutic agents has increased significantly. Capecitabine has huge potential to meet the growing need for new agents, which can more aggressively treat breast cancer in the earlier stages. However, the high cost of capecitabine, adverse effects, presence of substitutes, such as raltitrexed and leucovorin, and stringent government regulations related to the safety and efficacy of capecitabine hamper the market growth. Continuing R&D activities related to capecitabine are expected to present new opportunities for the market. This report covers a comprehensive overview, market shares, and growth opportunities of global capecitabine market by drug formulation, application, key players and key regions. Tablets segment expected to grow at the highest XX% CAGR during the forecast period owing to high production by manufacturers. Capecitabine is a medicine used to treat breast cancer and cancer of the colon or rectum. Capecitabine belongs to a group of drugs called antimetabolites which work by interfering with DNA production, stopping cells from reproducing. Breast cancer segment is expected to dominate because breast cancer is the most common malignancy in women, accounting for nearly XX% of all cancers in British women. Approximately XX% of all patients treated with curative intent will develop metastatic disease and the average survival time for these patients is 18–24 months. Also, approximately XX% of patients present with metastatic disease at first diagnosis. North America is expected to dominate the capecitabine market owing to the increasing prevalence of cancer in the region. Nearby 1,735,350 new cases of cancer were reported in 2018, National Cancer Institute. Various players are engaged in developing better treatment options. Such as, Puma Biotechnology has received positive results from the company’s lead drug Neratinib used in breast cancer. The treatment includes combination therapy with capecitabine. Europe is the second-largest capecitabine market globally. This can be attributed to the increasing incidences of cancers, which is the second leading cause of death and morbidity in Europe. Around XX Mn new cases occur each year in Europe. Global Capecitabine Market1 The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Capecitabine Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Global Capecitabine Market.

Scope of the Global Capecitabine Market: Inquire before buying

Global Capecitabine Market, By Drug Formulation

• Tablets • Capsules

Global Capecitabine Market, By Application

• Colon Cancer • Rectal Cancer • Breast Cancer • Gastric Cancer • Others

Global Capecitabine Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Capecitabine Market

• Fresenius SE & Co. KGaA • Genentech, Inc. • Dr Reddy Laboratories Ltd. • Cipla Inc. • Accord Healthcare Ltd. • F. Hoffmann-La Roche Ltd. • Teva Pharma B.V., Sandoz Inc. • Zentiva N.V. • Ranbaxy Laboratories Ltd. • Roche • Mylan • Hikma • Hengrui Medicine • Reliance Group • Hetero • Sandoz • Novartis AG • Sensus healthcare • RXi Pharmaceuticals, Inc. • Perrigo Company PLC • Pacific World Corporation • Revitol Corporation • Avita Medical Limited

Global Capecitabine Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Capecitabine Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Capecitabine Market Analysis and Forecast 6.1. Global Capecitabine Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Capecitabine Market Analysis and Forecast, By Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Capecitabine Market Value Share Analysis, By Application 7.4. Global Capecitabine Market Size (US$ Mn) Forecast, By Application 7.5. Global Capecitabine Market Analysis, By Application 7.6. Global Capecitabine Market Attractiveness Analysis, By Application 8. Global Capecitabine Market Analysis and Forecast, By Drug Formulation 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Capecitabine Market Value Share Analysis, By Drug Formulation 8.4. Global Capecitabine Market Size (US$ Mn) Forecast, By Drug Formulation 8.5. Global Capecitabine Market Analysis, By Drug Formulation 8.6. Global Capecitabine Market Attractiveness Analysis, By Drug Formulation 9. Global Capecitabine Market Analysis, by Region 9.1. Global Capecitabine Market Value Share Analysis, by Region 9.2. Global Capecitabine Market Size (US$ Mn) Forecast, by Region 9.3. Global Capecitabine Market Attractiveness Analysis, by Region 10. North America Capecitabine Market Analysis 10.1. Key Findings 10.2. North America Capecitabine Market Overview 10.3. North America Capecitabine Market Value Share Analysis, By Application 10.4. North America Capecitabine Market Forecast, By Application 10.4.1. Colon Cancer 10.4.2. Rectal Cancer 10.4.3. Breast Cancer 10.4.4. Gastric Cancer 10.4.5. Others 10.5. North America Capecitabine Market Value Share Analysis, By Drug Formulation 10.6. North America Capecitabine Market Forecast, By Drug Formulation 10.6.1. Tablets 10.6.2. Capsules 10.7. North America Capecitabine Market Value Share Analysis, by Country 10.8. North America Capecitabine Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Capecitabine Market Analysis, by Country 10.10. U.S. Capecitabine Market Forecast, By Application 10.10.1. Colon Cancer 10.10.2. Rectal Cancer 10.10.3. Breast Cancer 10.10.4. Gastric Cancer 10.10.5. Others 10.11. U.S. Capecitabine Market Forecast, By Drug Formulation 10.11.1. Tablets 10.11.2. Capsules 10.12. Canada Capecitabine Market Forecast, By Application 10.12.1. Colon Cancer 10.12.2. Rectal Cancer 10.12.3. Breast Cancer 10.12.4. Gastric Cancer 10.12.5. Others 10.13. Canada Capecitabine Market Forecast, By Drug Formulation 10.13.1. Tablets 10.13.2. Capsules 10.14. North America Capecitabine Market Attractiveness Analysis 10.14.1. By Application 10.14.2. By Drug Formulation 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Capecitabine Market Analysis 11.1. Key Findings 11.2. Europe Capecitabine Market Overview 11.3. Europe Capecitabine Market Value Share Analysis, By Application 11.4. Europe Capecitabine Market Forecast, By Application 11.4.1. Colon Cancer 11.4.2. Rectal Cancer 11.4.3. Breast Cancer 11.4.4. Gastric Cancer 11.4.5. Others 11.5. Europe Capecitabine Market Value Share Analysis, By Drug Formulation 11.6. Europe Capecitabine Market Forecast, By Drug Formulation 11.6.1. Tablets 11.6.2. Capsules 11.6.3. Europe Capecitabine Market Value Share Analysis, by Country 11.7. Europe Capecitabine Market Forecast, by Country 11.7.1. Germany 11.7.2. U.K. 11.7.3. France 11.7.4. Italy 11.7.5. Spain 11.7.6. Rest of Europe 11.8. Europe Capecitabine Market Analysis, by Country 11.9. Germany Capecitabine Market Forecast, By Application 11.9.1. Colon Cancer 11.9.2. Rectal Cancer 11.9.3. Breast Cancer 11.9.4. Gastric Cancer 11.9.5. Others 11.10. Germany Capecitabine Market Forecast, By Drug Formulation 11.10.1. Tablets 11.10.2. Capsules 11.11. U.K. Capecitabine Market Forecast, By Application 11.11.1. Colon Cancer 11.11.2. Rectal Cancer 11.11.3. Breast Cancer 11.11.4. Gastric Cancer 11.11.5. Others 11.12. U.K. Capecitabine Market Forecast, By Drug Formulation 11.12.1. Tablets 11.12.2. Capsules 11.13. France Capecitabine Market Forecast, By Application 11.13.1. Colon Cancer 11.13.2. Rectal Cancer 11.13.3. Breast Cancer 11.13.4. Gastric Cancer 11.13.5. Others 11.14. France Capecitabine Market Forecast, By Drug Formulation 11.14.1. Tablets 11.14.2. Capsules 11.15. Italy Capecitabine Market Forecast, By Application 11.15.1. Colon Cancer 11.15.2. Rectal Cancer 11.15.3. Breast Cancer 11.15.4. Gastric Cancer 11.15.5. Others 11.16. Italy Capecitabine Market Forecast, By Drug Formulation 11.16.1. Tablets 11.16.2. Capsules 11.17. Spain Capecitabine Market Forecast, By Application 11.17.1. Colon Cancer 11.17.2. Rectal Cancer 11.17.3. Breast Cancer 11.17.4. Gastric Cancer 11.17.5. Others 11.18. Spain Capecitabine Market Forecast, By Drug Formulation 11.18.1. Tablets 11.18.2. Capsules 11.19. Rest of Europe Capecitabine Market Forecast, By Application 11.19.1. Colon Cancer 11.19.2. Rectal Cancer 11.19.3. Breast Cancer 11.19.4. Gastric Cancer 11.19.5. Others 11.20. Rest of Europe Capecitabine Market Forecast, By Drug Formulation 11.20.1. Tablets 11.20.2. Capsules 11.21. Europe Capecitabine Market Attractiveness Analysis 11.21.1. By Application 11.21.2. By Drug Formulation 11.22. PEST Analysis 11.23. Key Trend 11.24. Key Development 12. Asia Pacific Capecitabine Market Analysis 12.1. Key Findings 12.2. Asia Pacific Capecitabine Market Overview 12.3. Asia Pacific Capecitabine Market Value Share Analysis, By Application 12.4. Asia Pacific Capecitabine Market Forecast, By Application 12.4.1. Colon Cancer 12.4.2. Rectal Cancer 12.4.3. Breast Cancer 12.4.4. Gastric Cancer 12.4.5. Others 12.5. Asia Pacific Capecitabine Market Value Share Analysis, By Drug Formulation 12.6. Asia Pacific Capecitabine Market Forecast, By Drug Formulation 12.6.1. Tablets 12.6.2. Capsules 12.7. Asia Pacific Capecitabine Market Value Share Analysis, by Country 12.8. Asia Pacific Capecitabine Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Capecitabine Market Analysis, by Country 12.10. China Capecitabine Market Forecast, By Application 12.10.1. Colon Cancer 12.10.2. Rectal Cancer 12.10.3. Breast Cancer 12.10.4. Gastric Cancer 12.10.5. Others 12.11. China Capecitabine Market Forecast, By Drug Formulation 12.11.1. Tablets 12.11.2. Capsules 12.12. India Capecitabine Market Forecast, By Application 12.12.1. Colon Cancer 12.12.2. Rectal Cancer 12.12.3. Breast Cancer 12.12.4. Gastric Cancer 12.12.5. Others 12.13. India Capecitabine Market Forecast, By Drug Formulation 12.13.1. Tablets 12.13.2. Capsules 12.14. Japan Capecitabine Market Forecast, By Application 12.14.1. Colon Cancer 12.14.2. Rectal Cancer 12.14.3. Breast Cancer 12.14.4. Gastric Cancer 12.14.5. Others 12.15. Japan Capecitabine Market Forecast, By Drug Formulation 12.15.1. Tablets 12.15.2. Capsules 12.16. ASEAN Capecitabine Market Forecast, By Application 12.16.1. Colon Cancer 12.16.2. Rectal Cancer 12.16.3. Breast Cancer 12.16.4. Gastric Cancer 12.16.5. Others 12.17. ASEAN Capecitabine Market Forecast, By Drug Formulation 12.17.1. Tablets 12.17.2. Capsules 12.18. Rest of Asia Pacific Capecitabine Market Forecast, By Application 12.18.1. Colon Cancer 12.18.2. Rectal Cancer 12.18.3. Breast Cancer 12.18.4. Gastric Cancer 12.18.5. Others 12.19. Rest of Asia Pacific Capecitabine Market Forecast, By Drug Formulation 12.19.1. Tablets 12.19.2. Capsules 12.20. Asia Pacific Capecitabine Market Attractiveness Analysis 12.20.1. By Application 12.20.2. By Drug Formulation 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Capecitabine Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Capecitabine Market Overview 13.3. Middle East & Africa Capecitabine Market Value Share Analysis, By Application 13.4. Middle East & Africa Capecitabine Market Forecast, By Application 13.4.1. Colon Cancer 13.4.2. Rectal Cancer 13.4.3. Breast Cancer 13.4.4. Gastric Cancer 13.4.5. Others 13.5. Middle East & Africa Capecitabine Market Value Share Analysis, By Drug Formulation 13.6. Middle East & Africa Capecitabine Market Forecast, By Drug Formulation 13.6.1. Tablets 13.6.2. Capsules 13.7. Middle East & Africa Capecitabine Market Value Share Analysis, by Country 13.8. Middle East & Africa Capecitabine Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Capecitabine Market Analysis, by Country 13.10. GCC Capecitabine Market Forecast, By Application 13.10.1. Colon Cancer 13.10.2. Rectal Cancer 13.10.3. Breast Cancer 13.10.4. Gastric Cancer 13.10.5. Others 13.11. GCC Capecitabine Market Forecast, By Drug Formulation 13.11.1. Tablets 13.11.2. Capsules 13.12. South Africa Capecitabine Market Forecast, By Application 13.12.1. Colon Cancer 13.12.2. Rectal Cancer 13.12.3. Breast Cancer 13.12.4. Gastric Cancer 13.12.5. Others 13.13. South Africa Capecitabine Market Forecast, By Drug Formulation 13.13.1. Tablets 13.13.2. Capsules 13.14. Rest of Middle East & Africa Capecitabine Market Forecast, By Application 13.14.1. Colon Cancer 13.14.2. Rectal Cancer 13.14.3. Breast Cancer 13.14.4. Gastric Cancer 13.14.5. Others 13.15. Rest of Middle East & Africa Capecitabine Market Forecast, By Drug Formulation 13.15.1. Tablets 13.15.2. Capsules 13.16. Middle East & Africa Capecitabine Market Attractiveness Analysis 13.16.1. By Application 13.16.2. By Drug Formulation 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Capecitabine Market Analysis 14.1. Key Findings 14.2. South America Capecitabine Market Overview 14.3. South America Capecitabine Market Value Share Analysis, By Application 14.4. South America Capecitabine Market Forecast, By Application 14.4.1. Colon Cancer 14.4.2. Rectal Cancer 14.4.3. Breast Cancer 14.4.4. Gastric Cancer 14.4.5. Others 14.5. South America Capecitabine Market Value Share Analysis, By Drug Formulation 14.6. South America Capecitabine Market Forecast, By Drug Formulation 14.6.1. Tablets 14.6.2. Capsules 14.7. South America Capecitabine Market Value Share Analysis, by Country 14.8. South America Capecitabine Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Capecitabine Market Forecast, By Application 14.9.1. Colon Cancer 14.9.2. Rectal Cancer 14.9.3. Breast Cancer 14.9.4. Gastric Cancer 14.9.5. Others 14.10. Brazil Capecitabine Market Forecast, By Drug Formulation 14.10.1. Tablets 14.10.2. Capsules 14.11. Mexico Capecitabine Market Forecast, By Application 14.11.1. Colon Cancer 14.11.2. Rectal Cancer 14.11.3. Breast Cancer 14.11.4. Gastric Cancer 14.11.5. Others 14.12. Mexico Capecitabine Market Forecast, By Drug Formulation 14.12.1. Tablets 14.12.2. Capsules 14.13. Rest of South America Capecitabine Market Forecast, By Application 14.13.1. Colon Cancer 14.13.2. Rectal Cancer 14.13.3. Breast Cancer 14.13.4. Gastric Cancer 14.13.5. Others 14.14. Rest of South America Capecitabine Market Forecast, By Drug Formulation 14.14.1. Tablets 14.14.2. Capsules 14.15. South America Capecitabine Market Attractiveness Analysis 14.15.1. By Application 14.15.2. By Drug Formulation 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Fresenius SE & Co. KGaA 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Manufacturing Footprint 15.3.2. Genentech, Inc. 15.3.3. Dr Reddy Laboratories Ltd. 15.3.4. Cipla Inc. 15.3.5. Accord Healthcare Ltd. 15.3.6. F. Hoffmann-La Roche Ltd. 15.3.7. Teva Pharma B.V., Sandoz Inc. 15.3.8. Zentiva N.V. 15.3.9. Ranbaxy Laboratories Ltd. 15.3.10. Roche 15.3.11. Mylan 15.3.12. Hikma 15.3.13. Hengrui Medicine 15.3.14. Reliance Group 15.3.15. Hetero 15.3.16. HSandoz 15.3.17. HNovartis AG 15.3.18. HSensus healthcare 15.3.19. HRXi Pharmaceuticals, Inc. 15.3.20. HPerrigo Company PLC 15.3.21. HPacific World Corporation 15.3.22. HRevitol Corporation 15.3.23. HAvita Medical Limited 16. Primary Key Insights

About This Report

Report ID34503
Category Healthcare
Published DateSept 2019
Updated Dateoct 2020
Contact Us